Mireille Delhase
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Mireille Delhase has a total of 90 co-authors. Here are the top co-authors by number of shared publications:
Michael Karin
Laboratory of Gene Regulation and Signal Transduction, Department of Pharmacology, University of California at San Diego School of Medicine, La Jolla, California 92093-0636
9 shared publications- Michael Karin
Department of Pharmacology, School of Medicine, University of California, San Diego, La Jolla, CA 92093, USA
3 shared publications Yi Chen
Laboratory of Gene Regulation and Signal Transduction, Department of Pharmacology, School of Medicine, University of California at San Diego, La Jolla, CA 92093-0723
3 shared publicationsAnagha Malur
2 shared publicationsB Velkeniers
2 shared publicationsE L Hooghe-Peters
2 shared publications
Latest Publications
- 1 January 2021
- Published by Springer Nature
- p. 1127-1136
NF-κB, Molecular Target
- 27 March 2020
- Published by Springer Nature
- p. 1-10
NF-κB, Molecular Target
- 27 December 2011
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 109 (4) , E177-E186
TANK-binding kinase 1 (TBK1) controls cell survival through PAI-2/serpinB2 and transglutaminase 2
The decision between survival and death in cells exposed to TNF relies on a highly regulated equilibrium between proapoptotic and antiapoptotic factors. The TNF-activated antiapoptotic response depends on several transcription factors, including NF-κB and its RelA/p65 subunit, that are activated through phosphorylation-mediated degradation of IκB inhibitors, a process controlled by the IκB kinase complex. Genetic studies in mice have identified the IκB kinase-related kinase TANK-binding kinase 1 (TBK1; also called NAK or T2K) as an additional regulatory molecule that promotes survival downstream of TNF, but the mechanism through which TBK1 exerts its survival function has remained elusive. Here we show that TBK1 triggers an antiapoptotic response by controlling a specific RelA/p65 phosphorylation event. TBK1-induced RelA phosphorylation results in inducible expression of plasminogen activator inhibitor-2 (PAI-2), a member of the serpin family with known antiapoptotic activity. PAI-2 limits caspase-3 activation through stabilization of transglutaminase 2 (TG2), which cross-links and inactivates procaspase-3. Importantly, Tg2 −/− mice were found to be more susceptible to apoptotic cell death in two models of TNF-dependent acute liver injury. Our results establish PAI-2 and TG2 as downstream mediators in the antiapoptotic response triggered upon TBK1 activation.
- 27 December 2011
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 109 (4) , E177-E186
TANK-binding kinase 1 (TBK1) controls cell survival through PAI-2/serpinB2 and transglutaminase 2
The decision between survival and death in cells exposed to TNF relies on a highly regulated equilibrium between proapoptotic and antiapoptotic factors. The TNF-activated antiapoptotic response depends on several transcription factors, including NF-κB and its RelA/p65 subunit, that are activated through phosphorylation-mediated degradation of IκB inhibitors, a process controlled by the IκB kinase complex. Genetic studies in mice have identified the IκB kinase-related kinase TANK-binding kinase 1 (TBK1; also called NAK or T2K) as an additional regulatory molecule that promotes survival downstream of TNF, but the mechanism through which TBK1 exerts its survival function has remained elusive. Here we show that TBK1 triggers an antiapoptotic response by controlling a specific RelA/p65 phosphorylation event. TBK1-induced RelA phosphorylation results in inducible expression of plasminogen activator inhibitor-2 (PAI-2), a member of the serpin family with known antiapoptotic activity. PAI-2 limits caspase-3 activation through stabilization of transglutaminase 2 (TG2), which cross-links and inactivates procaspase-3. Importantly, Tg2 −/− mice were found to be more susceptible to apoptotic cell death in two models of TNF-dependent acute liver injury. Our results establish PAI-2 and TG2 as downstream mediators in the antiapoptotic response triggered upon TBK1 activation.
- Open Access
- 10 September 2010
- Published by Springer Nature in The EMBO Journal
- Vol. 29 (20) , 3558-3570
Cooperative functions of Chk1 and Chk2 reduce tumour susceptibility in vivo
Although the linkage of Chk1 and Chk2 to important cancer signalling suggests that these kinases have functions as tumour suppressors, neither Chk1 +/− nor Chk2 −/− mice show a predisposition to cancer under unperturbed conditions. We show here that Chk1 +/− Chk2 −/− and Chk1 +/− Chk2 +/− mice have a progressive cancer‐prone phenotype. Deletion of a single Chk1 allele compromises G2/M checkpoint function that is not further affected by Chk2 depletion, whereas Chk1 and Chk2 cooperatively affect G1/S and intra‐S phase checkpoints. Either or both of the kinases are required for DNA repair depending on the type of DNA damage. Mouse embryonic fibroblasts from the double‐mutant mice showed a higher level of p53 with spontaneous DNA damage under unperturbed conditions, but failed to phosphorylate p53 at S23 and further induce p53 expression upon additional DNA damage. Neither Chk1 nor Chk2 is apparently essential for p53‐ or Rb‐dependent oncogene‐induced senescence. Our results suggest that the double Chk mutation leads to a high level of spontaneous DNA damage, but fails to eliminate cells with damaged DNA, which may ultimately increase cancer susceptibility independently of senescence.
- 10 September 2010
- Published by Springer Nature in The EMBO Journal
- Vol. 29 (20) , 3558-3570
Open AccessCooperative functions of Chk1 and Chk2 reduce tumour susceptibility in vivo
Although the linkage of Chk1 and Chk2 to important cancer signalling suggests that these kinases have functions as tumour suppressors, neither Chk1 +/− nor Chk2 −/− mice show a predisposition to cancer under unperturbed conditions. We show here that Chk1 +/− Chk2 −/− and Chk1 +/− Chk2 +/− mice have a progressive cancer‐prone phenotype. Deletion of a single Chk1 allele compromises G2/M checkpoint function that is not further affected by Chk2 depletion, whereas Chk1 and Chk2 cooperatively affect G1/S and intra‐S phase checkpoints. Either or both of the kinases are required for DNA repair depending on the type of DNA damage. Mouse embryonic fibroblasts from the double‐mutant mice showed a higher level of p53 with spontaneous DNA damage under unperturbed conditions, but failed to phosphorylate p53 at S23 and further induce p53 expression upon additional DNA damage. Neither Chk1 nor Chk2 is apparently essential for p53‐ or Rb‐dependent oncogene‐induced senescence. Our results suggest that the double Chk mutation leads to a high level of spontaneous DNA damage, but fails to eliminate cells with damaged DNA, which may ultimately increase cancer susceptibility independently of senescence.
- 1 January 2008
- Published by Springer Nature
- p. 884-889
Nuclear Factor Kappa B
- 1 November 2003
- Published by Taylor & Francis in Molecular and Cellular Biology
- Vol. 23 (21) , 7780-7793
Identification of NAP1, a Regulatory Subunit of IκB Kinase-Related Kinases That Potentiates NF-κB Signaling
The IκB kinase (IKK)-related kinase NAK (also known as TBK or T2K) contributes to the activation of NF-κB-dependent gene expression. Here we identify NAP1 (for NAK-associated protein 1), a protein that interacts with NAK and its relative IKKε (also known as IKKi). NAP1 activates NAK and facilitates its oligomerization. Interestingly, the NAK-NAP1 complex itself effectively phosphorylated serine 536 of the p65/RelA subunit of NF-κB, and this activity was stimulated by tumor necrosis factor alpha (TNF-α). Overexpression of NAP1 specifically enhanced cytokine induction of an NF-κB-dependent, but not an AP-1-dependent, reporter. Depletion of NAP1 reduced NF-κB-dependent reporter gene expression and sensitized cells to TNF-α-induced apoptosis. These results define NAP1 as an activator of IKK-related kinases and suggest that the NAK-NAP1 complex may protect cells from TNF-α-induced apoptosis by promoting NF-κB activation.
- 1 November 2003
- Published by Taylor & Francis in Molecular and Cellular Biology
- Vol. 23 (21) , 7780-7793
Identification of NAP1, a Regulatory Subunit of IκB Kinase-Related Kinases That Potentiates NF-κB Signaling
The IκB kinase (IKK)-related kinase NAK (also known as TBK or T2K) contributes to the activation of NF-κB-dependent gene expression. Here we identify NAP1 (for NAK-associated protein 1), a protein that interacts with NAK and its relative IKKε (also known as IKKi). NAP1 activates NAK and facilitates its oligomerization. Interestingly, the NAK-NAP1 complex itself effectively phosphorylated serine 536 of the p65/RelA subunit of NF-κB, and this activity was stimulated by tumor necrosis factor alpha (TNF-α). Overexpression of NAP1 specifically enhanced cytokine induction of an NF-κB-dependent, but not an AP-1-dependent, reporter. Depletion of NAP1 reduced NF-κB-dependent reporter gene expression and sensitized cells to TNF-α-induced apoptosis. These results define NAP1 as an activator of IKK-related kinases and suggest that the NAK-NAP1 complex may protect cells from TNF-α-induced apoptosis by promoting NF-κB activation.
- 1 October 2003
- Published by Elsevier in Molecular Cell
- Vol. 12 (4) , 829-839
CK2 Is a C-Terminal IκB Kinase Responsible for NF-κB Activation during the UV Response
- 1 October 2003
- Published by Elsevier in Molecular Cell
- Vol. 12 (4) , 829-839
CK2 Is a C-Terminal IκB Kinase Responsible for NF-κB Activation during the UV Response
- 31 December 2002
- Published by Springer Nature
- Vol. 225, 7-18
IκB Kinase and NF-κB Signaling in Response to Pro-Inflammatory Cytokines
- 31 December 2002
- Published by Springer Nature
- Vol. 225, 7-18
IκB Kinase and NF-κB Signaling in Response to Pro-Inflammatory Cytokines
- Top Cited Papers
The Lymphotoxin-β Receptor Induces Different Patterns of Gene Expression via Two NF-κB Pathways
- 25 February 2002
- Published by Informa Healthcare in Expert Opinion on Therapeutic Targets
- Vol. 6 (1) , 115-121
The Cytokine Odyssey 2001, a joint meeting of the Society of Leukocyte Biology and the International Cytokine Society
The Cytokine Odyssey 2001 was held at the Outrigger Wailea Resort in Maui, Hawaii, USA. The meeting, jointly sponsored by the International Cytokine Society (ICS, 9th Annual Meeting) and the Society of Leukocyte Biology (SLB, 35th Annual Meeting), was organised by Carl Ware (Chair) from the La Jolla Institute for Allergy and Immunology (La Jolla, USA) and Thomas Hamilton (Co-Chair) from the Cleveland Clinic Foundation (Cleveland, USA). This international conference was designed to bring together leading investigators in molecular and cellular biology, physiology and genetics, interested in cytokines and cells of the immune system. This forum was aimed to assess the impact of this expanding science on new approaches to disease intervention [1].
- 25 February 2002
- Published by Informa Healthcare in Expert Opinion on Therapeutic Targets
- Vol. 6 (1) , 115-121
The Cytokine Odyssey 2001, a joint meeting of the Society of Leukocyte Biology and the International Cytokine Society
The Cytokine Odyssey 2001 was held at the Outrigger Wailea Resort in Maui, Hawaii, USA. The meeting, jointly sponsored by the International Cytokine Society (ICS, 9th Annual Meeting) and the Society of Leukocyte Biology (SLB, 35th Annual Meeting), was organised by Carl Ware (Chair) from the La Jolla Institute for Allergy and Immunology (La Jolla, USA) and Thomas Hamilton (Co-Chair) from the Cleveland Clinic Foundation (Cleveland, USA). This international conference was designed to bring together leading investigators in molecular and cellular biology, physiology and genetics, interested in cytokines and cells of the immune system. This forum was aimed to assess the impact of this expanding science on new approaches to disease intervention [1].